Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19.

Şenkal N., Meral R., Medetalibeyoğlu A., Konyaoğlu H., Kose M., Tukek T.

Anatolian journal of cardiology, vol.24, no.1, pp.21-29, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 24 Issue: 1
  • Publication Date: 2020
  • Doi Number: 10.14744/anatoljcardiol.2020.57431
  • Journal Name: Anatolian journal of cardiology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.21-29
  • Keywords: coronavirus disease 2019, angiotensin-converting enzyme 2, angiotensin II receptor type 1 blockers, angiotensin-converting enzyme inhibitors, ANGIOTENSIN-CONVERTING ENZYME-2, SARS-CORONAVIRUS, FUNCTIONAL RECEPTOR
  • Istanbul University Affiliated: Yes


Objective: Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Renin-angiotensin-aldosterone-system (RAAS) inhibitors may increase the expression of angiotensin-converting enzyme 2, which is the receptor for SARSCoV-2 Spike protein. The consequences of using angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) during the COVID-19 pandemic are unknown.